- Conditions
- Breast Cancer, Overweight or Obesity
- Interventions
- Contrave, Behavioral Weight Loss
- Drug · Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®)
- Other · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Loss-of-Control Eating, Obesity/Overweight
- Interventions
- Naltrexone and Bupropion (NB) medication, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Binge-Eating Disorder
- Interventions
- Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Naltrexone-Bupropion Combination
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Loss-of-control Eating, Obesity/Overweight
- Interventions
- Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Healthy
- Interventions
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Nicotine Dependence, Overweight, Obesity
- Interventions
- NB32, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Encino, California • Los Alamitos, California • Newport Beach, California
- Conditions
- Obesity, Cardiovascular Diseases
- Interventions
- Naltrexone HCl/Bupropion HCl ER, Placebo
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 139
- States / cities
- Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Naltrexone and Bupropion, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Intervention Control, Counselling, Contrave, Contrave and Counseling
- Behavioral · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Scottsbluff, Nebraska
- Conditions
- Stimulant Use, Relapse, Cognitive Function, ADHD
- Interventions
- Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Binge-eating Disorder, Obesity
- Interventions
- NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- NB medication (Naltrexone Bupropion combination), Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity, Overweight
- Interventions
- NB32, PBO, Weight Management Program
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 8,910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
- Conditions
- Obesity
- Interventions
- Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana